Table 2.
Cox regression analysis for overall survival grouped by low or high baseline levels using the median as a cutoff value
| Overall survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| N | n | age-adjusted HR |
95% CI | p value | multivariable-adjusted HRa |
95% CI | p value | ||
| NRP-1 | ng/ml | ||||||||
| Low | ≤ 236.3 | 26 | 13 | 1 | 1 | ||||
| High | > 236.3 | 27 | 26 | 2.78 | 1.40–5.53 | 0.003 | 2.54 | 1.11–5.82 | 0.02 |
| PlGF | pg/ml | ||||||||
| Low | ≤ 24.7 | 27 | 18 | 1 | 1 | ||||
| High | > 24.7 | 26 | 21 | 2.08 | 0.99–4.37 | 0.05 | 3.11 | 1.30–7.47 | 0.01 |
| VEGF-A | pg/ml | ||||||||
| Low | ≤ 101.9 | 26 | 18 | 1 | 1 | ||||
| High | > 101.9 | 27 | 21 | 1.45 | 0.76–2.75 | 0.25 | 1.24 | 0.62–2.45 | 0.53 |
| VEGF-C | ng/ml | ||||||||
| Low | ≤ 1.6 | 28 | 20 | 1 | 1 | ||||
| High | > 1.6 | 25 | 19 | 1.12 | 0.59–2.11 | 0.71 | 1.06 | 0.53–2.14 | 0.85 |
| VEGF-D | pg/ml | ||||||||
| Low | ≤ 260.5 | 26 | 18 | 1 | 1 | ||||
| High | > 260.5 | 27 | 21 | 1.24 | 0.65–2.39 | 0.50 | 0.95 | 0.45–2.01 | 0.91 |
| VEGFR-1 | pg/ml | ||||||||
| Low | ≤ 125.5 | 27 | 17 | 1 | 1 | ||||
| High | > 125.5 | 26 | 22 | 1.90 | 0.98–3.67 | 0.05 | 1.10 | 0.50–2.40 | 0.79 |
| VEGFR-2 | ng/ml | ||||||||
| Low | ≤ 11.0 | 27 | 20 | 1 | 1 | ||||
| High | > 11.0 | 26 | 19 | 0.77 | 0.41–1.46 | 0.43 | 0.65 | 0.33–1.28 | 0.22 |
| VEGFR-3 | ng/ml | ||||||||
| Low | ≤ 43.5 | 27 | 16 | 1 | 1 | ||||
| High | > 43.5 | 26 | 23 | 2.34 | 1.23–4.47 | 0.01 | 1.81 | 0.88–3.73 | 0.10 |
Abbreviations: N = number of patients, n = number of events, HR = hazard ratio, CI = confidence interval
aMultivariable-adjusted hazard ratio adjusted by age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of the disease